These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36341432)

  • 1. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
    Saha A; Blazar BR
    Front Immunol; 2022; 13():1031334. PubMed ID: 36341432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.
    Saha A; Hyzy S; Lamothe T; Hammond K; Clark N; Lanieri L; Bhattarai P; Palchaudhuri R; Gillard GO; Proctor J; Riddle MJ; Panoskaltsis-Mortari A; MacMillan ML; Wagner JE; Kiem HP; Olson LM; Blazar BR
    Blood; 2022 Mar; 139(11):1743-1759. PubMed ID: 34986233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

  • 5. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.
    Saha A; Palchaudhuri R; Lanieri L; Hyzy S; Riddle MJ; Panthera J; Eide CR; Tolar J; Panoskaltsis-Mortari A; Gorfinkel L; Tkachev V; Gerdemann U; Alvarez-Calderon F; Palato ER; MacMillan ML; Wagner JE; Kean LS; Osborn MJ; Kiem HP; Scadden DT; Olson LM; Blazar BR
    Blood; 2024 May; 143(21):2201-2216. PubMed ID: 38447038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
    Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
    Maris M; Storb R
    Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
    Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
    Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.
    Chan YY; Ho PY; Swartzrock L; Rayburn M; Nofal R; Thongthip S; Weinberg KI; Czechowicz A
    Transplant Cell Ther; 2023 Mar; 29(3):164.e1-164.e9. PubMed ID: 35995393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
    Straathof KC; Rao K; Eyrich M; Hale G; Bird P; Berrie E; Brown L; Adams S; Schlegel PG; Goulden N; Gaspar HB; Gennery AR; Landais P; Davies EG; Brenner MK; Veys PA; Amrolia PJ
    Lancet; 2009 Sep; 374(9693):912-20. PubMed ID: 19729196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
    Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
    Maris M; Storb R
    Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.